Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: committee papers
Table of Contents
01 Response to consultee, commentator and public comments on the ACD
02 Consultee and commentator comments on the Appraisal Consultation from Novartis
03 Consultee and commentator comments on the Appraisal Consultation from BAD
04 Consultee and commentator comments on the Appraisal Consultation from RCPATH
05 Consultee and commentator comments on the Appraisal Consultation from RCGP
06 Consultee and commentator comments on the Appraisal Consultation from NHS England (Dermatology CRG)
07 Comments on the Appraisal Consultation Document from experts from Deborah Shipman
08 Comments on the ACD received through the NICE website
![Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: committee papers](/proxy/?sourceUrl=http%3a%2f%2fwww.nice.org.uk%2fimages%2ficons%2fpdf.gif)
|
Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: committee papers
11 March 2015 (1.19 Mb 56 sec) |
This page was last updated: 06 March 2015